Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights
Traws Pharma reported Q2 revenue of $0 compared to $2.7 million in the prior year, while net loss widened to $3.0 million or $0.16 per share due to higher G&A expenses. Cash and cash equivalents increased to $5.0 million following an April private placement, providing a runway into Q1 2027 before additional financing may be required. Shareholders approved Series B and C warrant tranches, granting the company access to up to $50 million in additional capital contingent on achieving clinical and regulatory milestones.
Key figures
- Revenue
- 0
- Net loss
- 3054000
- Ga expenses
- 3479000
- Rd expenses
- 1101000
- Cash balance
- 5016000
- Financing upfront
- 10000000
- Shares outstanding
- 15368277
- Warrants potential
- 50000000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.